Sunesis Pharmaceuticals Inc., of South San Francisco, was issued a notice of allowance for a patent claiming certain compositions related to the company's lead drug candidate, vosaroxin, as well as the final product related to such compositions

Allon Therapeutics Inc., of Vancouver, British Columbia, was granted a patent covering the use of its neuroprotective technology platform in the treatment of peripheral neuropathy, including lead drug candidate davunetide and pipeline product AL-309

8,088,376, which covers antibody drug candidates and engineering technology to impart specific therapeutic properties, including antibody-dependent cell cytotoxicity, immunomodulation and increased half-life and efficacy

Allon Therapeutics Inc., of Vancouver, British Columbia, received a patent covering the use of its drug candidates, including lead candidate davunetide, for treating laser-induced retinal damage

7,879,802 covering Synergy's drug candidate SP-333 to treat inflammatory bowel disease

7,872,105 B2 for the non-small-cell lung cancer-specific antibody component of its L-DOS47 drug candidate

7,862,812 related to Asonep, one of the company's two lead drug candidates

7,829,577, which covers pharmaceutical compositions of lead drug candidate vosaroxin

7,776,845, which covers its lead metabolic disease and anti-inflammatory drug candidate Triolex (HE3286

7,728,117, covering GMI-1070, its drug candidate being tested in patients with vaso-occlusive crisis of sickle cell disease

Celladon Corp., of La Jolla, Calif., was granted a notice of allowance for a patent covering lead drug candidate Mydicar, a genetically targeted enzyme replacement therapy for advanced heart failure

7,514,405, titled "Methods for treating transplant rejection," which covers the treatment of chronic transplant rejection by administering drug candidate VT-111 in combination with an immunosuppressant

7,524,829 and 7,507,196, which cover its drug candidate for Ebola Zaire infection, specifically composition and methods to target the Ebola virus VP35 protein with a range of PMOplus compounds

Tranzyme Pharma, of Research Triangle Park, N.C., received three patents covering its current and future drug candidates: U.S. Patent No

OPKO Health Inc., of Miami, was issued a patent covering methods related to the use and administration of small interfering RNAs for targeting vascular endothelial growth factor, including the company's siRNA drug candidate, bevasiranib, in Phase III studies in wet age-related macular degeneration

7,285,573, which covers the use of the company's drug candidates against amyotrophic lateral sclerosis

7,282,476, which covers the composition of PRX302, the company's lead drug candidate from its PORxin technology platform and its use in prostate cancer

7,276,505, covering its rheumatoid arthritis drug candidate RhuDex...The patent will cover six drug candidates capable of inhibiting HIV from infecting human cells

It extends protection covering the company's intranasal ketamine drug candidates into 2023...Rexahn Pharmaceuticals Inc., of Rockville, Md., received a patent for use of its drug candidate RX-10100 IR, or Zoraxel, to treat sexual dysfunction